Find information on thousands of medical conditions and prescription drugs.

Neurofibromatosis type 2

Neurofibromatosis Type II (or "MISME Syndrome", for "Multiple Inherited Schwannomas, Meningiomas, and Ependymomas") is an inherited disease. The main manifestation of the disease is the development of symmetric, non-malignant brain tumours in the region of the cranial nerve VIII, which is the auditory nerve that transmits sensory information from the inner ear to the brain. Most people with this condition also experience problems in their eyes. NF II is caused by mutations of a gene which probably influences the form and movement of cells. The principal treatments consist of neurosurgical removal of the tumors and surgical treatment of the eye lesions. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
N
Narcolepsy
Necrophobia
Necrotizing fasciitis
Neisseria meningitidis
Nemaline myopathy
Neonatal hemochromatosis
Neophobia
Nephophobia
Nephrogenic diabetes...
Nephrotic syndrome
Neuraminidase deficiency
Neurasthenia
Neuroacanthocytosis
Neuroblastoma
Neurofibrillary tangles
Neurofibroma
Neurofibromatosis
Neurofibromatosis type 2
Neuroleptic malignant...
Niemann-Pick Disease
Nijmegen Breakage Syndrome
Nocardiosis
Noma
Non-Hodgkin lymphoma
Noonan syndrome
Norrie disease
Nosophobia
Nyctophobia
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

There is no therapy for the underlying disorder of cell function caused by the genetic mutation.

Causes

Incidence, Mode of transmission, Epidemiology

NF II is an inheritable disorder with an autosomal dominant mode of transmission. Incidence of the disease is about 1 in 35,000. There is a broad clinical spectrum known, but all patients checked have been found to have the same mutation of a gene on chromosome 22. It is suspected that statistically, one half of cases are inherited, and one half are the result of new, de novo mutations.

Pathogenesis, Molecular Biology and pathophysiological relations

NF II is caused by a defect in the gene that normally gives rise to a product called "Merlin" or "Schwannomin", located on chromosome 22 band q11-13.1. This peptide is thought to have a tumor-suppressive function. The NF II gene is presumed to result in either a failure to synthesize Merlin, or the production of a defective peptide that lacks the normal tumor suppressive effect. The Schwannomin-peptide consists of 595 amino acids. Comparison of Schwannomin with other proteins shows similarities to proteins that connect the cytoskeleton to the cell membrane. Mutations in the Schwannomin-gene are thought to alter the movement and shape of affected cells with loss of contact inhibition.

Pathology

The so called acoustic neuroma of NF II is in fact a Schwannoma of the nervus vestibularis. The wrong term is used despite better knowledge in the whole scientific and medical literature. The vestibular Schwannomas grow slowly at the inner entrance of the internal auditory meatus (meatus acousticus internus). They derive from the nerve sheaths of the upper part of the nervus vestibularis in the region between the central and peripheral myelin (Obersteiner-Redlich-Zone) within the area of the porus acousticus, 1 cm from the brainstem.

Genotype-Phenotype-Correlation

Many patients with NF II were included in studies which were designed to compare disease type and progression with exact determination of the associated mutation. The goal of such comparisons of genotype and phenotype is to determine whether specific mutations cause respective combinations of symptoms. This would be extremely valuable for the prediction of disease progression and planning of therapy even at children age. The results of such studies are the following:

  • In most cases the mutation in the NF II gene causes shortened peptides.
  • There are no mutational hot-spots.
  • Patients with Frameshiftmutation- or Nonsense mutations suffer poor prognosis.
  • Patients with Missense mutations have a better prognosis.
  • In cases with Mutations in the splice-acceptor-region there is no good correlation to determine.
  • Point mutations may have only minor effects.
  • Cases are published in which exactly the same mutation is associated with clearly different outcome.

These results suggest, that probably other factors (Environment, other mutations) will determine the clinical outcome.

Read more at Wikipedia.org


[List your site here Free!]


Neurofibromatosis
From Gale Encyclopedia of Medicine, 4/6/01 by Rosalyn S. Carson-DeWitt

Definition

Neurofibromatosis (NF), or von Recklinghausen disease, is a genetic disease in which patients develop multiple soft tumors (neurofibromas). These tumors occur under the skin and throughout the nervous system.

Description

Neural crest cells are primitive cells which exist during fetal development. These cells eventually turn into:

  • Cells which form nerves throughout the brain, spinal cord, and body.
  • Cells which serve as coverings around the nerves that course through the body.
  • Pigment cells, which provide color to structures.
  • The meninges, the thin, membranous coverings of the brain and spinal cord.
  • Cells which ultimately develop into the bony structures of the head and neck.

In neurofibromatosis, a genetic defect causes these neural crest cells to develop abnormally. This results in numerous tumors and malformations of the nerves, bones, and skin.

Neurofibromatosis occurs in about one of every 4,000 births. Two types of NF exist, NF-1 (90% of all cases), and NF-2 (10% of all cases).

Causes & symptoms

Both forms of neurofibromatosis are caused by a defective gene. NF-1 is due to a defect on chromosome 17; NF-2 results from a defect on chromosome 22. Both of these disorders are inherited in a dominant fashion. This means that anybody who receives just one defective gene will have the disease. However, a family pattern of NF is only evident for about half of all cases of NF. The other cases of NF occur due to a spontaneous mutation (a permanent change in the structure of a specific gene). Once such a spontaneous mutation has been established in an individual, however, it is then possible to be passed on to any offspring. The chance of a person with NF passing on the NF gene to a child is 50%.

NF-1 has a number of possible signs and can be diagnosed if any two of the following are present:

  • The presence of café-au-lait (French for coffee-with-milk) spots. These are patches of tan or light brown skin, usually about 5-15 mm in diameter. Nearly all patients with NF-1 will display these spots.
  • Multiple freckles in the armpit or groin area.
  • Ninty percent of patients with NF-1 have tiny tumors called Lisch nodules in the iris (colored area) of the eye.
  • Neurofibromas. These soft tumors are the hallmark of NF-1. They occur under the skin, often located along nerves or within the gastrointestinal tract. Neurofibromas are small and rubbery, and the skin overlying them may be somewhat purple in color.
  • Skeletal deformities, such as a twisted spine (scoliosis), curved spine (humpback), or bowed legs.
  • Tumors along the optic nerve, which cause vision disturbance in about 20% of patients.
  • The presence of NF-1 in a patient's parent, child, or sibling.

There are very high rates of speech impairment, learning disabilities, and attention deficit disorder in children with NF-1. Other complications include the development of a seizure disorder, or the abnormal accumulation of fluid within the brain (hydrocephalus). A number of cancers are more common in patients with NF-1. These include a variety of types of malignant brain tumors, as well as leukemia, and cancerous tumors of certain muscles (rhabdomyosarcoma), the adrenal glands (pheochromocytoma), or the kidneys (Wilms' tumor).

Patients with NF-2 do not necessarily have the same characteristic skin symptoms (café-au-lait spots, freckling, and neurofibromas of the skin) that appear in NF-1. The characteristic symptoms of NF-2 are due to tumors along the acoustic nerve. Interfering with the function of this nerve results in the loss of hearing; and the tumor may spread to neighboring nervous system structures, causing weakness of the muscles of the face, headache, dizziness, poor balance, and uncoordinated walking. Cloudy areas on the lens of the eye (called cataracts) frequently develop at an unusually early age. As in NF-1, the chance of brain tumors developing is unusually high.

Diagnosis

Diagnosis is based on the symptoms outlined above. Diagnosis of NF-1 requires that at least two of the listed signs are present. Diagnosis of NF-2 requires the presence of either a mass on the acoustic nerve or another distinctive nervous system tumor. An important diagnostic clue for either NF-1 or NF-2 is the presence of the disorder in a patient's parent, child, or sibling.

Monitoring the progression of neurofibromatosis involves careful testing of vision and hearing. X-ray studies of the bones are frequently done to watch for the development of deformities. CT scans and MRI scans are performed to track the development/progression of tumors in the brain and along the nerves. Auditory evoked potentials (the electric response evoked in the cerebral cortex by stimulation of the acoustic nerve) may be helpful to determine involvement of the acoustic nerve, and EEG (electroencephalogram, a record of electrical currents in the brain) may be needed for patients with suspected seizures.

Treatment

There are no available treatments for the disorders which underlie either type of neurofibromatosis. To some extent, the symptoms of NF-1 and NF-2 can be treated individually. Skin tumors can be surgically removed. Some brain tumors, and tumors along the nerves, can be surgically removed, or treated with drugs (chemotherapy) or x-ray treatments (radiation therapy). Twisting or curving of the spine and bowed legs may require surgical treatment, or the wearing of a special brace.

Prognosis

Prognosis varies depending on the types of tumors which an individual develops. As tumors grow, they begin to destroy surrounding nerves and structures. Ultimately, this destruction can result in blindness, deafness, increasingly poor balance, and increasing difficulty with the coordination necessary for walking. Deformities of the bones and spine can also interfere with walking and movement. When cancers develop, prognosis worsens according to the specific type of cancer.

Prevention

There is no known way to prevent the approximately 50% of all NF cases which occur due to a spontaneous change in the genes (mutation). New cases of inherited NF can be prevented with careful genetic counseling. A person with NF can be made to understand that each of his or her offspring has a 50% chance of also having NF. When a parent has NF, and the specific genetic defect causing the parent's disease has been identified, tests can be performed on the fetus (developing baby) during pregnancy. Amniocentesis or chorionic villus sampling are two techniques which allow small amounts of the baby's cells to be removed for examination. The tissue can then be examined for the presence of the parent's genetic defect. Some families choose to use this information in order to prepare for the arrival of a child with a serious medical problem. Other families may choose not to continue the pregnancy.

Key Terms

Chromosome
A structure within the nucleus of every cell, which contains genetic information governing the organism's development.
Mutation
A permanent change to the genetic code of an organism. Once established, a mutation can be passed on to offspring.
Neurofibroma
A soft tumor usually located on a nerve.
Tumor
An abnormally multiplying mass of cells.

Further Reading

For Your Information

    Books

  • Haslam, Robert H.A. "Neurocutaneous Syndromes." In Nelson Textbook of Pediatrics, edited by Richard Behrman. Philadelphia: W.B. Saunders Co., 1996.

    Periodicals

  • "Health Supervision for Children with Neurofibromatosis." Pediatrics 96, 2 (August 1995): 368+.
  • Levy, Charles E. "Physiatry and Care of Patients with Neurofibromatosis." The Journal of the American Medical Association 278, 18 (November 12, 1997): 1493+.
  • Waller, Amy L., and James E. Baumgartner. "Current Concepts in the Management of Neurofibromatosis Type 1." Physician Assistant 21, 8 (August 1997): 103+.

    Organizations

  • March of Dimes Birth Defects Foundation. National Office, 1275 Mamaroneck Avenue, White Plains, NY 10605. http://222.modimes.org.
  • The National Neurofibromatosis Foundation, Inc., 95 Pine St., 16th Floor, New York, NY 10005. (800)323-7938. http://nf.org.
  • Neurofibromatosis, Inc., 8855 Annapolis Rd., #110, Lanham, MD 20706-2924. (800) 942-6825.

Gale Encyclopedia of Medicine. Gale Research, 1999.

Return to Neurofibromatosis type 2
Home Contact Resources Exchange Links ebay